Answer
Women of childbearing potential taking gilteritinib fumarate should use effective contraception (pregnancy rate below 1%) during treatment and for 6 months afterward, add a barrier method if using hormonal contraception because its effectiveness may be reduced, and have pregnancy testing 7 days before starting treatment.
Sources for this answer
- Gilteritinib Astellas 40 mg film-coated tabletsAstellas Pharma Ltd · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 7Document updated
Sources checked